blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4190333

EP4190333 - AZELASTINE AS ANTIVIRAL TREATMENT [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  08.12.2023
Database last updated on 27.07.2024
FormerThe application has been published
Status updated on  05.05.2023
Most recent event   Tooltip28.05.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
CEBINA GmbH
Karl-Farkas-Gasse 22
1030 Vienna / AT
[2023/23]
Inventor(s)01 / NAGY, Eszter
1070 Vienna / AT
02 / NAGY, Gábor
9400 Sopron / HU
03 / SZIJARTO, Valeria
1160 Wien / AT
04 / KONRAT, Robert
1040 Vienna / AT
 [2023/23]
Representative(s)Redl, Gerda, et al
REDL Life Science Patent Attorneys
Donau-City-Straße 11
1220 Wien / AT
[2023/23]
Application number, filing date22206040.228.05.2021
[2023/23]
Priority number, dateEP2020017745129.05.2020         Original published format: EP 20177451
EP2020018476708.07.2020         Original published format: EP 20184767
EP2020019574011.09.2020         Original published format: EP 20195740
EP2021017133329.04.2021         Original published format: EP 21171333
[2023/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4190333
Date:07.06.2023
Language:EN
[2023/23]
Search report(s)(Supplementary) European search report - dispatched on:EP08.05.2023
ClassificationIPC:A61K31/55, A61P31/14
[2023/23]
CPC:
A61K31/55 (EP,IL,KR,US); A61K45/06 (US); A61K9/0043 (US);
A61K9/0073 (US); A61P11/00 (EP,IL,KR); A61P31/14 (EP,IL,KR,US);
A61P31/16 (KR); A61K2300/00 (IL); Y02A50/30 (EP) (-)
C-Set:
A61K31/55, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/02]
Former [2023/23]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:AZELASTIN ZUR ANTIVIRALEN BEHANDLUNG[2023/23]
English:AZELASTINE AS ANTIVIRAL TREATMENT[2023/23]
French:AZELASTINE DESTINÉ AU TRAITEMENT ANTIVIRAL[2023/23]
Examination procedure01.12.2023Amendment by applicant (claims and/or description)
01.12.2023Examination requested  [2024/02]
01.12.2023Date on which the examining division has become responsible
Parent application(s)   TooltipEP21727186.5  / EP3934653
Fees paidRenewal fee
26.05.2023Renewal fee patent year 03
27.05.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]JP2008285474  (DAIICHI SANKYO HEALTHCARE CO) [X] 1-10,13-15 * the whole document, in particular * * paragraphs [0001] , [00 3] - [0005] - [00 7] - [0013] - [0 19] - [0029] * * Examples * * Claims * [I] 11,12;
 [X]WO2010025236  (GOLDIN ALEXANDER [US]) [X] 1-15 * the whole document * * in particular * * page 1, line 20 - line 35 * * page 2, line 25 - line 31 * * page 5, line 18 - page 6, line 18 * * page 7, line 7 - line 34 * * Studies & Study Results * * figure - *;
 [AP]  - DEISY MORSELLI GYSI ET AL, "Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, (20200809), XP081735380 [AP] 1-15 * in particular * * 'Discussion' * * page 8, paragraph 2 * * table 1 * * Compound 10 * * table 2 * * figure 3 *
 [A]  - HASANAIN ABDULHAMEED ODHAR, "Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus", BIOINFORMATION, (20200331), vol. 16, no. 3, doi:10.6026/97320630016236, ISSN 0973-8894, pages 236 - 244, XP055757879 [A] 1-15 * the whole document * * in particular * * abstract * * table 2 * * figures 6-10 * * 'Results and Discussion' *

DOI:   http://dx.doi.org/10.6026/97320630016236
 [AP]  - Xia Xiao ET AL, "Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2", bioRxiv, doi:10.1101/2020.07.06.188953, (20200706), URL: https://www.biorxiv.org/content/10.1101/2020.07.06.188953v1.full.pdf, XP055757691 [AP] 1-15 * the whole document * * in particular * * abstract * * 'Results' * * 'Discussion' * * figure 2 * * tables 1, 2 *

DOI:   http://dx.doi.org/10.1101/2020.07.06.188953
 [XP]  - Robert Konrat ET AL, "The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro", bioRxiv, doi:10.1101/2020.09.15.296228, (20200915), URL: https://www.biorxiv.org/content/10.1101/2020.09.15.296228v1.full.pdf, (20201208), XP055757689 [XP] 1-15 * the whole document * * in particular also * * page 8 *

DOI:   http://dx.doi.org/10.1101/2020.09.15.296228
 [I]  - SIMON MICHAEL W, "The efficacy of azelastine in the prophylaxis of acute upper respiratory tract infections", PEDIATRIC ASTHMA ALLERGY & IMMUNOLOGY, (20030101), vol. 16, no. 4, ISSN 0883-1874, pages 275 - 282, XP009528870 [I] 1-15 * the whole document * * in particular * * abstract * * 'Results' * * 'Discussion' *

DOI:   http://dx.doi.org/10.1089/088318703322751327
 [A]  - FU L.-L. ET AL, "In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy", CELL PROLIFERATION, GB, (20140626), vol. 47, no. 4, doi:10.1111/cpr.12117, ISSN 0960-7722, pages 326 - 335, XP055826571 [A] 1-15 * in particular * * abstract * * table 1 * * 'Results', in particular 'Anti-HBV effects and NTCP regulation by azelastine hydrochloride (N4)' on p 333 * * 'Discussion' *

DOI:   http://dx.doi.org/10.1111/cpr.12117
 [A]  - Drugs.Com, "Azelastine - FDA prescribing information, side effects and uses", (20160820), URL: https://web.archive.org/web/20160820225031/https://www.drugs.com/pro/azelastine.html, (20230426), XP093042278 [A] 1-15 * the whole document * * in particular * * "Azelastine Description' on p. 6, §§ 3-5 *
by applicant   - ODHAR et al., Bioinformation, (20200000), vol. 16, no. 3, pages 236 - 244
    - FU et al., Cell Prolif., (20140000), vol. 47, pages 326 - 335
    - M. W. SIMON, Pediatric Asthma, Allergy & Immunology, (20030000), vol. 16, pages 275 - 282
    - "NCBI", Database accession no. QII57161.1
    - CAS , no. 58581-89-8
    - GREGORI-PUIGJANE, E.MESTRES, J. SHED, "Shannon Entropy Descriptors from Topological Feature Distributions", J.Chem.lnf.Model., (20060000), vol. 46, pages 1615 - 1622
    - WISHART, DS.KNOX, C.GUO, ACCHENG, D.SHRIVASTAVA, S.TZUR, D.GAUTAM, B.HASSANALI, M., "DrugBank: a knowledgebase for drugs, drug action and drug targets", Nucleic Acids Res., (20080000), doi:10.1093/nar/gkm958, pages D901 - D906, XP055757274

DOI:   http://dx.doi.org/10.1093/nar/gkm958
    - ZHOU, YHOU, Y.SHEN, JHUANG, Y.MARTIN, W.CHENG, F., "Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2", Cell Discovery, (20200000), vol. 6, doi:10.1038/s41421-020-0153-3, pages 14 - 32, XP055726866

DOI:   http://dx.doi.org/10.1038/s41421-020-0153-3
    - ADEDEJI, AO.SEVERSON, W.JONSSON, C.SINGH, K.WEISS SR.SARAFANOS, SG, "Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms", J Virol., (20130000), vol. 87, doi:10.1128/JVI.00998-13, pages 8017 - 8028, XP055757276

DOI:   http://dx.doi.org/10.1128/JVI.00998-13
    - RIEPLER et al., "Comparison of Four SARS-CoV-2 Neutralization Assays", Vaccines (Basel, (20200000), vol. 9, no. 1, doi:10.3390/vaccines9010013, page 13, XP055818101

DOI:   http://dx.doi.org/10.3390/vaccines9010013
    - HOFFMANN et al., Nature, (20200000), vol. 585, pages 588 - 590
    - T. GRUNWALD, Fraunhofer Institute for Cell Therapy and Immunology
    - WILMSCHEN et al., Vaccines, (20190000), vol. 7, page 59
    - BODA et al., Antiviral Research, (20180000), vol. 156, pages 72 - 79
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.